Recent studies have shown that SHP2 inhibition specifically suppresses the growth capacity of KRAS-mutant, but not wt NSCLC cells in vitro, which is promoted by TKI treatment (8, 11, 65–67). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.